XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.3
EQUITY AND NONCONTROLLING INTERESTS - Schedule of Earnings Per Share (Details) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 27, 2025
Sep. 28, 2024
Sep. 27, 2025
Sep. 28, 2024
Numerator:        
Net income $ 55,556 $ 70,295 $ 134,127 $ 239,038
Less: Net income attributable to noncontrolling interests 1,134 638 1,910 2,340
Net income attributable to Charles River Laboratories International, Inc. 54,422 69,657 132,217 236,698
Calculation of net income per share attributable to Charles River Laboratories International, Inc. common shareholders        
Net income attributable to Charles River Laboratories International, Inc. 54,422 69,657 132,217 236,698
Less: Adjustment of redeemable noncontrolling interests 0 379 0 1,081
Less: Incremental dividends attributed to noncontrolling interest holders 0 599 0 9,621
Net income available to Charles River Laboratories International, Inc. common shareholders $ 54,422 $ 68,679 $ 132,217 $ 225,996
Denominator:        
Weighted-average shares outstanding - Basic (in shares) 49,213 51,394 49,680 51,461
Effect of dilutive securities:        
Stock options, restricted stock units and performance share units (in shares) 213 189 186 252
Weighted-average shares outstanding - Diluted (in shares) 49,426 51,583 49,866 51,713
Anti-dilutive common stock equivalents (in shares) 1,131 746 1,057 505